Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 607-233-2 | CAS number: 2343-89-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In recently conducted, reliable, guideline studies, the substance showed moderate acute toxicity to Wistar rats by the oral dose route (LD50 = 50 - 300 mg/kg) and low acute toxicity by the dermal dose route (LD50 >2000 mg/kg). Testing by the inhalation route was not justified based on the likely use and exposure.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 12/5/15 to 2/6/15
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harla Laboratories UK Ltd., Oxon, UK
- Age at study initiation: 8-12 weeks
- Weight at study initiation: 179.2 g (variation not exceeding ±20%)
- Fasting period before study: Overnight
- Housing: Suspended solid-floor polypropylene cages furnished with woodflakes
- Diet (e.g. ad libitum): Free access to 1014C Teklad Global Rodent diet
- Water (e.g. ad libitum): Free access to main drinking water
- Acclimation period: At least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 25 °C
- Humidity (%): 30 to 70 %
- Air changes (per hr): Fifteen changes per hour
- Photoperiod (hrs dark / hrs light): 12 hours dark, twleve hours light - Route of administration:
- oral: gavage
- Vehicle:
- arachis oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 5 mg/ml
- Amount of vehicle (if gavage):
- Justification for choice of vehicle: Arachis oil BP used as the test substance did not dissolve/suspend in distilled water
MAXIMUM DOSE VOLUME APPLIED: 50 mg/kg, 5 mg/ml. - Doses:
- An initial sighting test was conducted aty 300 mg/kg. However, the test animal was killed for humane reasons due to the occurence of clinical signs of toxicity that exceeded the severity limit set forth in the UK Home Office Project Literature.
A dose of 50 mg/kg was than administeered. No mortality was recorded at this level. - No. of animals per sex per dose:
- 5 animals
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical observations were made 30 minutes, 1, 2 and 4 hours after dosing, and then daily. Individual body weights were checked on Day 0, Day 7 and Day 14 or at death.
- Necropsy of survivors performed: Yes - Preliminary study:
- An intial dosing of 300 mg/kg was used in one rat, however this animal was killed for humane reasons one day after dosing due to it showing a severe toxicological effect.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- >= 50 - <= 300 mg/kg bw
- Based on:
- act. ingr.
- Mortality:
- Outside of one death at the initial 300 mg/kg dose, no mortality was recorded.
- Clinical signs:
- other: Signs of systemic toxicity noted in the animal treated at a dose level of 300 mg/kg were prostration, pallor of the extremities, pilo-erection, emaciation, decreased respiratory rate, labored respiration and hypothermia. There were no signs of systemic to
- Gross pathology:
- Pale liver and pale kidneys were noted at necropsy of the animal treated at a dose level of 300 mg/kg. No abnormalities were noted at necropsy of animals treated at a dose level of 50 mg/kg.
- Interpretation of results:
- Category 3 based on GHS criteria
- Conclusions:
- The acute oral median lethal dose (LD50) of the test item in the female Wistar strain rat was estimated to be in the range of 50 - 300 mg/kg.
- Executive summary:
Introduction
The study was performed to assess the acute oral toxicity of the test item in the Wistar strain rat.
Methods
Following a sighting test at dose levels of 300 mg/kg and 50 mg/kg, a further group of four fasted females was given a single oral dose of test item, as a solution in arachis oil BP, at a dose level of 50 mg/kg body weight. Clinical signs and body weight development were monitored during the study. All animals were subjected to gross necropsy.
Results
Mortality. The animal treated at a dose level of 300 mg/kg was killed for humane reasons, 1 day after dosing, due to the occurrence of clinical signs of toxicity that exceeded the severity limit set forth in the UK Home Office Project Licence. There were no deaths noted at a dose level of 50 mg/kg.
Clinical Observations. Signs of systemic toxicity noted in the animal treated at a dose level of 300 mg/kg were prostration, pallor of the extremities, pilo-erection, emaciation, decreased respiratory rate, labored respiration and hypothermia. There were no signs of systemic toxicity at a dose level of 50 mg/kg.
Body Weight. Two animals showed body weight loss or no gain in body weight during the first week with expected gain in body weight during the second week. One other animal showed expected gain in body weight during the first week but body weight loss during the second week. Two animals showed expected gains in body weight over the study period.
Necropsy. Pale liver and pale kidneys were noted at necropsy of the animal treated at a dose level of 300 mg/kg. No abnormalities were noted at necropsy of animals treated at a dose level of 50 mg/kg.
Conclusion
The acute oral median lethal dose (LD50) of the test item in the female Wistar strain rat was estimated to be in the range of 50 - 300 mg/kg body weight (Globally Harmonized Classification System - Category 3).
Reference
Table 1 Individual Clinical Observations and Mortality Data - 300 mg/kg
Dose level | Animal number and sex | Effects noted after dosing (hours) | Effects noted during period after dosing | |||
0.5 | 1 | 2 | 4 | 1 day | ||
300 mg/kg | 1 -0 Female | 0 | 0 | 0 | 0 | Prostration,Pallor of the extremities, Pilo-erection, Emaciation, Decreased respiratory rate, Laboured respiration, Hypothermia. Animal killed for humane reasons. |
Table 2 Individual Body Weights and Body Weight Changes - 300 mg/kg
Dose level | Animal number and sex | Body weight at day 0 | Body weight at death | |||
300 mg/kg | 1 -0 Female | 168 g | 160 6 g |
Table 3 Individual Necropsy Findings - 300 mg/kg
Does level | Animal number and sex | Time of death | Macroscopic Observations |
300 mg/kg | 1 -0 Female | Humanely killed Day 1 | Liver: Pale, Kidneys: Pale |
Table 4 Individual Clinical Observations and Mortality Data - 50 mg/kg
Dose level | Animal number and sex | Effects noted after dosing (hours) | Effects noted during period after dosing (days) | ||||||||||||||||
0.5 | 1 | 2 | 4 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ||
50 mg/kg | 2 -0 Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
50 mg/kg | 3 -0 Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
50 mg/kg | 3 -1 Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
50 mg/kg | 3 -2 Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
50 mg/kg | 3 -3 Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Table 5 Individual Body Weights and Body Weight Changes - 50 mg/kg
Dose level | Animal Number and Sex | Body weight at Day | Body Weight Gain During Week | |||
0 | 7 | 14 | 1 | 2 | ||
50 mg/kg | 2 -0 Female | 198 | 218 | 228 | 20 | 10 |
50 mg/kg | 3 -0 Female | 172 | 189 | 181 | 17 | -8 |
50 mg/kg | 3 -1 Female | 170 | 170 | 200 | 0 | 30 |
50 mg/kg | 3 -2 Female | 178 | 174 | 181 | -4 | 7 |
50 mg/kg | 3 -3 Female | 178 | 185 | 193 | 7 | 8 |
Table 6 Individual Necropsy Findings - 50 mg/kg
Dose level | Animal Number and Sex | Time of Death | Macroscopic Observatrions |
50 mg/kg | 2 -0 Female | Killed Day 14 | No abnormalities detected |
50 mg/kg | 3 -0 Female | Killed Day 14 | No abnormalities detected |
50 mg/kg | 3 -1 Female | Killed Day 14 | No abnormalities detected |
50 mg/kg | 3 -2 Female | Killed Day 14 | No abnormalities detected |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 300 mg/kg bw
- Quality of whole database:
- Sufficient to meet data requirements. The study is Klimisch 1.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- The substance is only used within closed industrial systems. Testing by the inhalation route is not justified given that exposure of humans via inhalation is unlikely.
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 18/5/15 to 4/6/15
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories UK Ltd., Oxon, UK
- Age at study initiation: 8 to 12 weeks
- Weight at study initiation: At least 200 g, weight variation did not exceed ±20% of the mean weight
- Fasting period before study: None
- Housing: uspended solid floor polypropylene cages furnished with woodflakes.
- Diet (e.g. ad libitum): Free access to 2014C Teklad Global Rodent diet
- Water (e.g. ad libitum): Free access to mains drinking water
- Acclimation period: At least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 25 °C
- Humidity (%): 30 to 70 %
- Air changes (per hr): At least 15 changes per hour
- Photoperiod (hrs dark / hrs light): 12 hours light/12 hours dark - Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: Shorn skin, precise location not specified
- % coverage: 10 % of the total body surface
- Type of wrap if used: surgical gauze, semi-occluded with a piece of self-ashesive bandage
REMOVAL OF TEST SUBSTANCE
- Washing (if done): Washed with cotton wool and arachis oil BP
- Time after start of exposure: 24 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg
- Constant volume or concentration used: yes - Duration of exposure:
- 24 hours
- Doses:
- Single dose test
- No. of animals per sex per dose:
- Five
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: 30 minutes, 1 hour, 2 hours and 4 hours after dosing and subsequently daily for the observation period
- Necropsy of survivors performed: yes - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- >= 2 000 mg/kg bw
- Based on:
- act. ingr.
- Mortality:
- There were no deaths.
- Clinical signs:
- other: No signs of systemic toxicity were noted during the observation period.
- Gross pathology:
- No abnormalities were noted at necropsy.
- Other findings:
- There were no signs of dermal irritation
- Interpretation of results:
- not classified
- Conclusions:
- The acute dermal median lethal dose (LD50) of the test item in the Wistar strain rat was found to be greater than 2000 mg/kg body weight. The substance is not classified according to the CLP Regulation (EU) 1272/2008.
- Executive summary:
Introduction
The study was performed to assess the acute dermal toxicity of the test item in the Wistar strain rat.
Methods
Initially, two animals (one male and one female) were given a single, 24 hour, semi-occluded dermal application of the undiluted test item to intact skin at a dose level of 2000 mg/kg body weight. Based on the results of the initial test, a further group of eight animals (four males and four females) was similarly treated. Clinical signs and body weight development were monitored during the study. All animals were subjected to gross necropsy.
Results
Mortality. There were no deaths.
Clinical Observations. There were no signs of systemic toxicity.
Dermal Irritation. There were no signs of dermal irritation.
Body Weight. Three females showed body weight loss or no gain in body weight during the first week with expected gain in body weight during the second week. The remaining animals showed expected gains in body weight over the study period.
Necropsy. No abnormalities were noted at necropsy.
Conclusion
The acute dermal median lethal dose (LD50) of the test item in the Wistar strain rat was found to be greater than 2000 mg/kg body weight.
Reference
Table 1 - Individual Clinical Observations and Mortality Data
Effects Noted After Dosing (Hours) | Effects Noted During Period After Dosing (Days) | ||||||||||||||||||
Dose Level (mg/kg) | Animal Number and Sex | 0.5 | 1 | 2 | 4 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
2000 | 1 -0 Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -0 Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -1 Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -2 Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -3 Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 2 -0 Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -0 Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -1 Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -2 Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -3 Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Table 2 - Individual Dermal Reactions: Males
Effects Noted After Initiation of Exposure (Days) |
||||||||||||||||
Dose Level (mg/kg) | Animal Number and Sex | Observation | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
2000 | 1 -0 Male | Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 1 -0 Male | Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 1 -0 Male | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -0 Male | Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -0 Male | Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -0 Male | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -1 Male | Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -1 Male | Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -1 Male | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -2 Male | Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -2 Male | Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -2 Male | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -3 Male | Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -3 Male | Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 3 -3 Male | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Table 3 - Individual Dermal Reactions: Females
Effects Noted After Initiation of Exposure (Days) | ||||||||||||||||
Dose Level (mg/kg) | Animal Number and Sex | Observation | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
2000 | 2 -0 Female | Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 2 -0 Female | Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 2 -0 Female | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -0 Female | Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -0 Female | Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -0 Female | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -1 Female | Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -1 Female | Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -1 Female | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -2 Female | Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -2 Female | Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -2 Female | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -3 Female | Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -3 Female | Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2000 | 4 -3 Female | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Table 4 - Individual Body Weights and Body Weight Changes
Body Weight (g) at Day | Body Weight Change (g) During Week | |||||
Dose Level (mg/kg) | Animal Number and Sex | 0 | 7 | 14 | 1 | 2 |
2000 |
1 -0 Male | 228 | 240 | 262 | 12 | 22 |
2000 | 3 -0 Male | 226 | 241 | 260 | 15 | 19 |
2000 | 3 -1 Male | 236 | 246 | 269 | 10 | 23 |
2000 | 3 -2 Male | 242 | 261 | 284 | 19 | 23 |
2000 | 3 -3 Male | 230 | 243 | 262 | 13 | 19 |
2000 | 2 -0 Female | 211 | 214 | 217 | 3 | 3 |
2000 | 4 -0 Female | 214 | 214 | 224 | 0 | 10 |
2000 | 4 -1 Female | 220 | 219 | 234 | -1 | 15 |
2000 | 4 -2 Female | 213 | 217 | 223 | 4 | 6 |
2000 | 4 -3 Female | 214 | 212 | 221 | -2 | 9 |
Table 5 - Individual Necropsy Findings
Dose Level (mg/kg) | Animal Number and Sex | Time of Death | Macroscopic Observations |
2000 | 1 -0 Male | Killed Day 14 | No abnormalities detected |
2000 | 3 -0 Male | Killed Day 14 | No abnormalities detected |
2000 | 3 -1 Male | Killed Day 14 | No abnormalities detected |
2000 | 3 -2 Male | Killed Day 14 | No abnormalities detected |
2000 | 3 -3 Male | Killed Day 14 | No abnormalities detected |
2000 | 2 -0 Female | Killed Day 14 | No abnormalities detected |
2000 | 4 -0 Female | Killed Day 14 | No abnormalities detected |
2000 | 4 -1 Female | Killed Day 14 | No abnormalities detected |
2000 | 4 -2 Female | Killed Day 14 | No abnormalities detected |
2000 | 4 -3 Female | Killed Day 14 | No abnormalities detected |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Sufficient to meet data requirements. The study is Klimisch 1.
Additional information
Justification for classification or non-classification
Based on the results of the available toxicity studies, the substance is classified for acute toxicity by the oral route (Acute Toxicity category 3, H301). Classification for the dermal route is not justified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.